As part of Stago's continuous improvement commitment, STA® -Liatest® D-Di Plus* was developed as an evolution of the STA® -Liatest® D-Di, on...
Rivaroxaban is a new oral anticoagulant, direct factor Xa inhibitor, developed by Bayer HealthCare and sold under the trade name Xarelto®. ...
For every Heparin Induced Thrombocytopenia (HIT) suspicion. A rapid and specific exclusion of Heparin Induced Thrombocytopenia in 10 minute...
This innovating test is an indirect marker of Tissue Factor exposure In Vivo.
Diagnostica Stago, the worldwide leader in the field of Haemostasis is setting the standard of excellence, with cutting-edge technologies, products and customer service. United Kingdom is one of the countries where research is the most advanced in the field of coagulation and the demand for new technologies is great. In January 2005, the subsidiary Diagnostica Stago UK was opened.
Stago’s first mission is to provide health professionals with reliable, powerful and innovative haemostasis diagnostic tools in looking for a way to improve prevention, understanding, diagnostic, treatment and follow-up of coagulation-related pathologies.
April 15th - 17th, 2013
June 29th - July 4th, 2013
September 3rd - 4th, 2013
Did you know?
Heparin was discovered independently in 1911 by Doyon and in 1916 by McLean, for different reasons. The effect of heparin on blood clotting, however, had been observed one-third of a century earlier.
We don't have any job openings at the moment. Please check back later.